A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin With 5 FU/LV [fluorouracil + folinic acid] Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer [H6Q-MC-S064].

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin With 5 FU/LV [fluorouracil + folinic acid] Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer [H6Q-MC-S064].

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2013

At a glance

  • Drugs Enzastaurin (Primary) ; Bevacizumab; Fluorouracil; Folinic acid
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jun 2012 Actual initiation date changed from 22 Jan 2008 to 28 Nov 2007 as reported by European Clinical Trials Database.
    • 21 Feb 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top